- Home
- SPHL vs BCAB Comparison
SPHL vs BCAB Comparison
Compare SPHL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPHL | BCAB |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.9M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPHL | BCAB |
|---|---|---|
| Price | $2.42 | $1.70 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.1K | ★ 116.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.12 |
| 52 Week High | $25.11 | $6.52 |
Technical Indicators
Market Signals| Indicator | SPHL | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 19.94 |
| Support Level | $2.19 | $0.17 |
| Resistance Level | $3.04 | $4.24 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 25.29 | 7.67 |
Price Performance
Historical ComparisonAbout SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd conducts its operations through its indirect wholly-owned subsidiary, which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of work, including new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment in the development of construction projects. It derives maximum revenue from its Residential Customers.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.